HTA ID Drug Brand Indication Assessment status Date
20052 Galcanezumab Emgality® For the prophylaxis of migraine in adults who have at least four migraine days per month. Assessment process complete 13th January 2021
- Gefitinib Iressa® For the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR. Assessment process complete 5th November 2010
- Gemtuzumab ozogamicin Mylotarg® For combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive AML, except acute promyelocytic leukaemia. Assessment process complete 4th July 2019
19043 Gilteritinib Xospata® For the treatment of adult patients with relapsed or refractory acute myeloid leukaemia (AML) with an FLT3 mutation. Assessment process complete 3rd March 2021
20041 Glasdegib Daurismo® In combination with LDAC (low-dose cytarabine), for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia in adult patients who are not candidates for standard induction chemotherapy. Rapid Review Complete 9th October 2020
- Glecaprevir/Pibrentasvir Maviret® For the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic GT1-6. Assessment process complete 17th August 2017
23055 Glofitamab Columvi® Glofitamab is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), after two or more lines of systemic therapy. Rapid Review Complete 3rd October 2023
- Glucosamine sulfate Dona® For the treatment of oestoarthritis in the Irish Healthcare setting. Assessment process complete 7th June 2009
- Glycerol phenylbutyrate Ravicti® For use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs). Assessment process complete 20th June 2018
- Glycopyrronium bromide Seebri Breezhaler® As a maintenance bronchodilator treatment to relieve symptoms in patients with chronic obstructive pulmonary disease (COPD). Assessment process complete 17th August 2012
- Glycopyrronium bromide Sialanar® For symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. Assessment process complete 13th June 2017
- Golimumab (Simponi®) For the treatment of moderate to severe rheumatoid arthritis. Assessment process complete 11th May 2010
- Golimumab Simponi® For the treatment of moderately-to-severely active UC in patients who have failed or are intolerant to conventional treatments. Assessment process complete 31st October 2013
- Grass pollen allergen extract Oralair® For the treatment of allergic grass pollen rhinitis with or without conjunctivitis in adults, adolescents and children (above the age of 5) with clinically relevant symptoms confirmed by a positive cutaneous test and/or a positive titre of the specific IgE to the grass pollen. Assessment process complete 13th October 2011
- Guanfacine hydrochloride Intuniv® For the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. Assessment process complete 18th December 2015
- Guselkumab Tremfya® For the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. Assessment process complete 6th February 2018
20059 Guselkumab Tremfya® For the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy. Assessment process complete 17th February 2021